Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
Children's Oncology Group
University of Florida
University of Florida
Cellectar Biosciences, Inc.
Children's National Research Institute
City of Hope Medical Center
Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
Stanford University
St. Jude Children's Research Hospital
Augusta University
The University of Texas Health Science Center, Houston
Jazz Pharmaceuticals
Seattle Children's Hospital
Seattle Children's Hospital
Novartis
Valent Technologies, LLC
Emory University
Duke University
National Cancer Institute (NCI)
City of Hope Medical Center
St. Jude Children's Research Hospital
Bambino Gesù Hospital and Research Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Istari Oncology, Inc.
University of California, San Francisco
National Cancer Institute (NCI)
Washington University School of Medicine
Y-mAbs Therapeutics
National Institutes of Health Clinical Center (CC)
Children's Oncology Group
Mayo Clinic
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Fudan University
Pediatric Brain Tumor Consortium
Pediatric Brain Tumor Consortium
Duke University
Oncurious NV
Novartis
Novartis
Novartis